C - Chemistry – Metallurgy – 07 – C
Patent
C - Chemistry, Metallurgy
07
C
C07C 211/27 (2006.01) A61K 31/13 (2006.01) A61K 31/135 (2006.01) A61K 31/27 (2006.01) A61K 31/335 (2006.01) A61K 31/381 (2006.01) A61P 25/00 (2006.01) A61P 25/24 (2006.01) C07C 215/44 (2006.01) C07C 255/46 (2006.01) C07D 277/28 (2006.01) C07D 307/36 (2006.01) C07D 333/24 (2006.01)
Patent
CA 2636324
The invention relates to novel cyclohexylamine derivatives and their use in the treatment and/or prevention of central nervous system (CNS) disorders, such as depression, anxiety, schizophrenia and sleep disorder as well as methods for their synthesis. The invention also relates to pharmaceutical compositions containing the compounds of the invention, as well as methods of inhibiting reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine from the synaptic cleft and methods of modulating one or more monoamine transporter.
L'invention concerne de nouveaux dérivés de cyclohéxylamine et leur utilisation dans le traitement et/ou la prévention des troubles du système nerveux central (SNC), tels que la dépression, l'anxiété, la schizophrénie et les troubles du sommeil, ainsi que des procédés de synthèse de ceux-ci. L'invention concerne également des compositions pharmaceutiques contenant les composés de l'invention, ainsi que des procédés d'inhibition du recaptage des monoamines endogènes, telles que la dopamine, la sérotonine et la norépinéphrine de la fente synaptique, et des procédés de modulation d'un ou de plusieurs transporteurs de monoamines.
Bush Larry R.
Campbell John E.
Campbell Una
Engel Sharon Rae
Hardy Larry Wendell
Gowling Lafleur Henderson Llp
Sepracor Inc.
Sunovion Pharmaceuticals Inc.
LandOfFree
Cycloalkylamines as monoamine reuptake inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cycloalkylamines as monoamine reuptake inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cycloalkylamines as monoamine reuptake inhibitors will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-2050400